Published in Cancer on March 15, 2007
Improving melanoma classification by integrating genetic and morphologic features. PLoS Med (2008) 2.52
Epidemiology of invasive cutaneous melanoma. Ann Oncol (2009) 2.21
Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer (2010) 1.37
Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer (2012) 1.19
Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol (2009) 1.18
Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study. J Transl Med (2011) 1.15
Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy. PLoS One (2013) 0.97
High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma. Diagn Pathol (2012) 0.97
Time course and pattern of metastasis of cutaneous melanoma differ between men and women. PLoS One (2012) 0.89
Incidence and mortality trends of melanoma in Croatia. Croat Med J (2012) 0.84
BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy. PLoS One (2014) 0.83
Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis. PLoS One (2013) 0.82
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
T-helper-1-cell cytokines drive cancer into senescence. Nature (2013) 4.47
Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight. Adv Exp Med Biol (2008) 4.12
Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol (2008) 3.71
Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: Review of the literature and recommendations for general practice. J Dtsch Dermatol Ges (2011) 2.82
Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol (2003) 2.81
Melanoma epidemiology and trends. Clin Dermatol (2008) 2.57
Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol (2003) 2.56
Improving melanoma classification by integrating genetic and morphologic features. PLoS Med (2008) 2.52
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist (2008) 2.22
Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. Cancer Immunol Immunother (2010) 2.18
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci (2005) 2.00
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol (2012) 1.97
Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol (2003) 1.78
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol (2008) 1.71
Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer (2010) 1.66
The natural course of cutaneous melanoma. J Surg Oncol (2004) 1.56
Images in clinical medicine. A medical mystery--skin discolorations in a bank employee. N Engl J Med (2007) 1.55
Histological and genetic evidence for a variant of superficial spreading melanoma composed predominantly of large nests. Mod Pathol (2012) 1.52
Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant metastasis after nodal involvement. Ann Surg Oncol (2009) 1.49
Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer (2008) 1.49
Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res (2010) 1.47
Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J Invest Dermatol (2002) 1.47
Rapid lump examination (RLE) - a new tool for Mohs surgery? J Dtsch Dermatol Ges (2011) 1.45
Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother (2009) 1.44
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res (2013) 1.43
Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group. Melanoma Res (2008) 1.40
Three dimensional (3D) histology in daily routine: practical implementation and its evaluation. J Dtsch Dermatol Ges (2014) 1.40
Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother (2008) 1.40
Confocal laser scanning microscopy vs 3-dimensional histologic imaging in basal cell carcinoma. Arch Dermatol (2010) 1.39
Dysplastic nevus syndrome with development of multiple melanomas. A surgical concept for prophylaxis. J Dtsch Dermatol Ges (2009) 1.38
The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. Cancer Res (2003) 1.37
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol (2008) 1.35
Current concepts in the classification, diagnosis and treatment of vascular anomalies. Eur J Radiol (2010) 1.30
Melanoma development and progression: a conspiracy between tumor and host. Differentiation (2002) 1.30
Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer (2007) 1.30
The incidence and mortality of cutaneous melanoma in Southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003. Cancer (2006) 1.30
Dermoscopy of tungiasis. Arch Dermatol (2004) 1.29
Epidemiology of skin cancer. Adv Exp Med Biol (2014) 1.29
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol (2005) 1.27
β-Catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance. PLoS One (2011) 1.25
Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". J Dtsch Dermatol Ges (2013) 1.25
Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene (2003) 1.23
Suppression of casein kinase 1alpha in melanoma cells induces a switch in beta-catenin signaling to promote metastasis. Cancer Res (2010) 1.23
Desmoplastic malignant melanoma: a clinicopathologic analysis of 113 cases. Am J Dermatopathol (2008) 1.20
Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Sci Signal (2013) 1.19
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med (2013) 1.19
Non-AIDS associated Kaposi's sarcoma: clinical features and treatment outcome. PLoS One (2011) 1.19
Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society. J Clin Oncol (2004) 1.18
Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol (2011) 1.17
Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo. J Immunol (2005) 1.16
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J Clin Oncol (2010) 1.14
The RacGEF Tiam1 inhibits migration and invasion of metastatic melanoma via a novel adhesive mechanism. J Cell Sci (2004) 1.14
Cathepsin D is present in human eccrine sweat and involved in the postsecretory processing of the antimicrobial peptide DCD-1L. J Biol Chem (2005) 1.12
The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer (2007) 1.10
Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. Pigment Cell Res (2003) 1.09
Reciprocal regulation of MelCAM and AKT in human melanoma. Oncogene (2003) 1.08
Risk factors of incident melanocytic nevi: a longitudinal study in a cohort of 1,232 young German children. Int J Cancer (2005) 1.08
Moderate sun exposure and nevus counts in parents are associated with development of melanocytic nevi in childhood: a risk factor study in 1,812 kindergarten children. Cancer (2003) 1.08
High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer (2010) 1.07
Plasmid DNA- and messenger RNA-based anti-cancer vaccination. Immunol Lett (2007) 1.07
Costs of the detection of metastases and follow-up examinations in cutaneous melanoma. Melanoma Res (2009) 1.05
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res (2008) 1.05